Colesevelam Shortage: What Providers and Prescribers Need to Know in 2026

Provider Briefing: Colesevelam Supply in 2026

Colesevelam (Welchol) — the bile acid sequestrant with dual FDA approval for hyperlipidemia and type 2 diabetes glycemic control — has faced intermittent supply disruptions in 2026. While not always reflected on formal shortage databases, the real-world impact on patient access has been significant. This briefing covers what you need to know to manage your patients through the current supply landscape.

Timeline: How We Got Here

Colesevelam supply issues are not new, but they've become more noticeable in recent years due to several converging factors:

• Manufacturing consolidation: The number of generic Colesevelam manufacturers has decreased over the past several years, concentrating production among fewer facilities.
• Intermittent production disruptions: Facility maintenance shutdowns, regulatory inspections, and raw material sourcing challenges have created periodic supply gaps.
• Regional distribution imbalances: Centralized pharmacy chain ordering systems can create localized shortages even when national supply is adequate.
• Evolving prescribing patterns: Increased interest in Colesevelam's glycemic benefits for type 2 diabetes has contributed to demand fluctuations that outpace supply adjustments.

Throughout 2026, the pattern has been intermittent rather than continuous — pharmacies may be out of stock for days or weeks before restocking. The FDA drug shortage database has not consistently listed Colesevelam, as disruptions tend to resolve before meeting formal shortage criteria.

Prescribing Implications

The supply situation introduces several clinical considerations:

Patient Adherence Risk

Patients who cannot fill their Colesevelam prescription face treatment interruptions that may lead to LDL cholesterol rebound and glycemic destabilization. While missing a few doses does not cause withdrawal effects, extended gaps can be clinically meaningful — particularly for patients using Colesevelam as part of a multi-drug regimen for cardiovascular risk reduction or diabetes management.

Prior Authorization Complications

Some insurance plans require prior authorization or step therapy (e.g., trying Cholestyramine first) before covering Colesevelam. During supply disruptions, these administrative barriers compound the problem. Document the shortage in the patient's chart and on prior authorization forms. Reference the FDA Drug Shortage Database or ASHP shortage listings as supporting documentation when available.

Formulation Flexibility

Colesevelam is available in three formulations: 625 mg tablets, 3.75 g oral suspension packets, and 3.75 g chewable bars. If one formulation is unavailable, another may be in stock. Consider writing prescriptions that allow pharmacist substitution between formulations when clinically appropriate.

Current Availability Picture

Availability in 2026 varies significantly by geography and pharmacy type:

• Chain pharmacies: Most susceptible to regional stock-outs due to centralized ordering systems. CVS, Walgreens, and Rite Aid locations may show inconsistent availability.
• Independent pharmacies: Often maintain better stock through flexible wholesaler relationships and direct ordering capabilities.
• Mail-order pharmacies: Generally have more stable supply through larger distribution networks.
• Hospital/clinic pharmacies: May have separate supply chains that are less affected by retail distribution issues.

For real-time stock data, Medfinder for Providers offers pharmacy availability searches that can be integrated into clinical workflows.

Cost and Access Considerations

Cost remains a significant factor in patient access to Colesevelam:

• Brand-name Welchol: Approximately $1,000–$1,100 per month (180 tablets at retail)
• Generic Colesevelam (retail): $400–$665 per month without discounts
• Generic with discount card: $41–$90 per month (GoodRx, SingleCare, and similar services)

Key programs to recommend to patients:

• Welchol Savings Card: Eligible commercially insured patients may pay as little as $0 per fill (welchol.com)
• Daiichi Sankyo Patient Assistance Program: Free medication for qualifying uninsured/underinsured patients through AccessCentral4U
• Discount cards: GoodRx, SingleCare, and RxSaver consistently show generic Colesevelam at $41–$90 for 180 tablets

For a comprehensive patient-facing resource on cost savings: How to Save Money on Colesevelam in 2026.

Tools and Resources for Providers

Several tools can help you and your staff manage the shortage efficiently:

Medfinder for Providers

Medfinder allows providers and staff to search for Colesevelam availability at pharmacies by location. This can be used proactively when writing a new prescription or reactively when a patient reports a fill failure. Consider sharing medfinder.com directly with patients so they can check availability themselves.

FDA and ASHP Resources

• FDA Drug Shortage Database: accessdata.fda.gov/scripts/drugshortages — for formal shortage listings and manufacturer updates
• ASHP Drug Shortage Resource Center: ashp.org/drug-shortages — for clinical alternatives and management guidelines

Therapeutic Alternatives Reference

When Colesevelam is unavailable, consider these evidence-based alternatives:

• Cholestyramine (Questran, Prevalite): Same drug class, lower cost. More GI side effects. Not FDA-approved for diabetes. Powder form only.
• Colestipol (Colestid): Same drug class. Available as tablets or granules. Not FDA-approved for diabetes.
• Ezetimibe (Zetia): Cholesterol absorption inhibitor. Well tolerated, convenient once-daily dosing. No bile acid sequestrant drug interactions. Not indicated for blood sugar.
• Statin dose adjustment: For patients already on a statin, increasing the dose may compensate for loss of Colesevelam's LDL-lowering effect.

For a patient-facing version of this alternatives discussion: Alternatives to Colesevelam If You Can't Fill Your Prescription.

Looking Ahead

The Colesevelam supply situation is expected to remain variable throughout 2026. Manufacturers have not announced major capacity expansions, and the factors driving intermittent disruptions — manufacturing consolidation, supply chain fragility, and regulatory pressures — are systemic rather than temporary.

Proactive strategies include:

• Prescribing with formulation flexibility when possible
• Educating patients about Medfinder and other availability tools
• Documenting shortage-related prescribing changes in the chart for continuity of care
• Considering 90-day mail-order prescriptions for stable patients
• Having a pre-identified alternative ready for patients who report fill failures

Final Thoughts

The intermittent nature of Colesevelam supply disruptions makes proactive management essential. Patients who lose access to this medication face real clinical consequences — rising LDL cholesterol and, for diabetic patients, potential glycemic destabilization. By staying informed about the supply landscape, having alternatives ready, and connecting patients with tools like Medfinder, providers can help ensure continuity of care even during availability gaps.

Additional clinical resources:

• How to Help Your Patients Find Colesevelam in Stock: A Provider's Guide
• Colesevelam Drug Interactions: What to Avoid
• How to Help Patients Save Money on Colesevelam: A Provider's Guide